Barr Labs
Executive Summary
Generic manufacturer and FDA are scheduled to resume hearings in Newark federal court on Sept. 10. The trial had been suspended on Aug. 19 while attorneys for both sides attempted to negotiate a settlement. Originally, FDA asked the court to demand a halt in the manufacturing of 15 products, improvements in Barr's production and process testing for 45 other products and the recall of 30 lots of products.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth